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BACKGROUND
Preterm preeclampsia is an important cause of maternal and perinatal death and 
complications. It is uncertain whether the intake of low-dose aspirin during preg-
nancy reduces the risk of preterm preeclampsia.
METHODS
In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 
1776 women with singleton pregnancies who were at high risk for preterm pre-
eclampsia to receive aspirin, at a dose of 150 mg per day, or placebo from 11 to 
14 weeks of gestation until 36 weeks of gestation. The primary outcome was de-
livery with preeclampsia before 37 weeks of gestation. The analysis was performed 
according to the intention-to-treat principle.
RESULTS
A total of 152 women withdrew consent during the trial, and 4 were lost to follow 
up, which left 798 participants in the aspirin group and 822 in the placebo group. 
Preterm preeclampsia occurred in 13 participants (1.6%) in the aspirin group, as 
compared with 35 (4.3%) in the placebo group (odds ratio in the aspirin group, 
0.38; 95% confidence interval, 0.20 to 0.74; P = 0.004). Results were materially 
unchanged in a sensitivity analysis that took into account participants who had 
withdrawn or were lost to follow-up. Adherence was good, with a reported intake 
of 85% or more of the required number of tablets in 79.9% of the participants. 
There were no significant between-group differences in the incidence of neonatal 
adverse outcomes or other adverse events.
CONCLUSIONS
Treatment with low-dose aspirin in women at high risk for preterm preeclampsia 
resulted in a lower incidence of this diagnosis than placebo. (Funded by the 
European Union Seventh Framework Program and the Fetal Medicine Foun-
dation; EudraCT number, 2013-003778-29; Current Controlled Trials number, 
ISRCTN13633058.)
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Preeclampsia is an important cause of death and complications for the mother and baby. The risk of such complications 
is considerably higher when the disease is severe 
and of early onset, leading to preterm birth at less 
than 37 weeks of gestation.1-4 Major challenges 
in modern obstetrics are the identification of 
women at high risk for preterm preeclampsia 
early in pregnancy and interventions to reduce 
the prevalence of the disease.
In 1979, a study showed that women who had 
taken aspirin regularly during pregnancy were 
less likely to have preeclampsia than women 
who had not.5 In the subsequent decades, more 
than 30 trials have investigated the benefit of low-
dose aspirin (at a dose of 50 to 150 mg per day) 
for the prevention of preeclampsia; a meta-analy-
sis of these studies showed that such therapy 
resulted in a 10% lower incidence of preeclamp-
sia.6 In a meta-analysis of individual-participant 
data from the trials, the effect of aspirin was not 
affected by the gestational age at the onset of 
therapy.7 In contrast, other meta-analyses showed 
that aspirin started at or before 16 weeks of 
gestation resulted in halving the rates of pre-
eclampsia, fetal-growth restriction, and perina-
tal death, whereas aspirin started after 16 weeks 
of gestation did not have a significant benefit.8,9 
In addition, the beneficial effect of aspirin that 
was started at or before 16 weeks of gestation 
was dose dependent, with a greater reduction in 
the incidence of preeclampsia being associated 
with a daily dose of aspirin of 100 mg or more.10
Professional associations now recommend the 
prophylactic use of low-dose aspirin (60 to 80 mg 
per day) in women who are considered to be at 
high risk for preeclampsia. In the United King-
dom, the National Institute for Health and Clini-
cal Excellence recommends the identification of 
the high-risk group on the basis of 10 factors, 
including maternal characteristics and features 
of the medical and obstetrical histories.11 How-
ever, the performance of such screening is poor, 
with detection of approximately 40% of cases of 
preterm preeclampsia and 33% of cases of term 
preeclampsia, at a screen-positive rate of 11%.12 
In the United States, the American College of 
Obstetricians and Gynecologists recommends 
the use of aspirin in women with a history of 
preeclampsia in more than one pregnancy or a 
history of preeclampsia that resulted in delivery 
before 34 weeks of gestation.13 However, this 
subgroup constitutes only approximately 0.3% of 
all pregnancies and includes only 5% of women 
in whom preterm preeclampsia develops and 2% 
of those in whom term preeclampsia develops.14 
An alternative approach to screening is the use 
of Bayes’ theorem to combine the a priori risk 
from maternal factors with biophysical and bio-
chemical measurements obtained at 11 to 13 weeks 
of gestation. A study involving approximately 
60,000 women with singleton pregnancies showed 
that such screening detected 76% of cases of 
preterm preeclampsia and 38% of cases of term 
preeclampsia, at a screen-positive rate of 10%.15 
The Combined Multimarker Screening and Ran-
domized Patient Treatment with Aspirin for Evi-
dence-Based Preeclampsia Prevention (ASPRE) trial 
was designed to test the hypothesis that, among 
women who are identified as being at high risk 
for preterm preeclampsia on the basis of the 
above-mentioned factors, aspirin at a dose of 
150 mg per day, taken from 11 to 14 weeks of 
gestation until 36 weeks of gestation, would re-
sult in an incidence of preterm preeclampsia that 
was half the incidence observed with placebo.
Me thods
Trial Design and Participants
In this double-blind, placebo-controlled trial, we 
compared aspirin at a dose of 150 mg per day 
with placebo that was administered from 11 to 
14 weeks of gestation until 36 weeks of gesta-
tion in women with singleton pregnancies who 
were at high risk for preterm preeclampsia. We 
conducted the trial at 13 maternity hospitals in 
the United Kingdom, Spain, Italy, Belgium, 
Greece, and Israel.
All the women who had a routine prenatal visit 
at 11 weeks 0 days of gestation through 13 weeks 
6 days of gestation in the participating hospitals 
were offered screening for preeclampsia by means 
of an algorithm that combines maternal factors, 
mean arterial pressure, uterine-artery pulsatility 
index, and maternal serum pregnancy-associated 
plasma protein A and placental growth factor. 
(The algorithm is provided in the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org.)15
Gestational age was determined from the 
measurement of the fetal crown–rump length.16 
The New England Journal of Medicine 
Downloaded from nejm.org at GE HEALTHCARE LTD. on July 28, 2017. For personal use only. No other uses without permission. 
 Copyright © 2017 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 3
Aspirin vs. Placebo for Preterm Preeclampsia
Maternal characteristics and medical and obstet-
rical histories were recorded, and the maternal 
weight and height were measured. The mean 
arterial pressure was measured by validated auto-
mated devices with the use of a standardized 
protocol.17 Transabdominal color Doppler ultra-
sonography was used to measure the left and 
right uterine-artery pulsatility index, and the 
average value was recorded.18 Serum concentra-
tions of pregnancy-associated plasma protein A 
and placental growth factor were measured by an 
automated device (PAPP-A and PlGF 1-2-3 kits and 
DELFIA Xpress random access platform, Perkin-
Elmer). Quality control was applied to achieve 
consistency of the measurement of biomarkers 
across trial centers. Quality control of screening 
and verification of adherence to the protocol 
were performed by the University College London 
Comprehensive Clinical Trials Unit.
Inclusion criteria for the trial were the follow-
ing: an age of 18 years or more, singleton preg-
nancy, live fetus at the time that scanning was 
performed at 11 to 13 weeks of gestation, and a 
high risk (>1 in 100) for preterm preeclampsia 
according to the screening algorithm. Exclusion 
criteria were the following: unconscious or severe-
ly ill status, learning difficulties or serious men-
tal illness, major fetal abnormality identified at 
the time that scanning was performed at 11 to 
13 weeks of gestation, regular treatment with 
aspirin within 28 days before screening, bleeding 
disorder such as von Willebrand’s disease, peptic 
ulceration, hypersensitivity to aspirin, long-term 
use of nonsteroidal antiinflammatory medication, 
and participation in another drug trial within 
28 days before screening. Potential trial partici-
pants were given written information about the 
trial, and those who agreed to participate pro-
vided written informed consent.
Approval for the trial was obtained from the 
relevant research ethics committee and compe-
tent authority in each country in which the trial 
was conducted. The trial was conducted with 
fidelity to the protocol, which is available, with 
the statistical analysis plan, at NEJM.org. The 
funding organizations and the companies that 
supplied and distributed the aspirin and placebo 
had no role in the trial design, the collection, 
analysis, or interpretation of the data, the writ-
ing of the manuscript, or the decision to submit 
the manuscript for publication. The authors vouch 
for the accuracy and completeness of the data 
and analyses.
Randomization and Trial-Group Assignment
Eligible women were randomly assigned, in a 1:1 
ratio, with the use of a Web-based system (Sealed 
Envelope), to receive either aspirin or placebo, 
and in the random-sequence generation there 
was stratification according to participating cen-
ter. The aspirin and placebo tablets were manu-
factured by Actavis UK and were packaged, labeled, 
stored, and distributed by Mawdsley-Brooks. The 
placebo tablets were identical to the aspirin tab-
lets with respect to variables such as size, thick-
ness, physical properties, and appearance. After 
randomization, the participants were prescribed 
the assigned trial product and received instruc-
tions to take one tablet every night throughout 
the trial and to stop taking tablets at 36 weeks 
of gestation or, in the event of early delivery, at 
the onset of labor.
Outcome Measures
The primary outcome measure was delivery with 
preeclampsia before 37 weeks of gestation. Pre-
eclampsia was defined according to the Interna-
tional Society for the Study of Hypertension in 
Pregnancy (see the Supplementary Appendix).19 
Secondary outcomes were adverse outcomes of 
pregnancy before 34 weeks of gestation, before 
37 weeks of gestation, and at or after 37 weeks 
of gestation; stillbirth or neonatal death; death 
and neonatal complications; neonatal therapy; 
and poor fetal growth (birth weight below the 3rd, 
5th, or 10th percentile) (Table S1 in the Supple-
mentary Appendix).20
Adverse Events and Adherence
Adverse events and adherence were assessed 
and recorded at follow-up clinical visits at 19 to 
24 weeks of gestation, 32 to 34 weeks of gesta-
tion, and 36 weeks of gestation and during three 
telephone interviews, which occurred at 16 weeks 
and 28 weeks of gestation and 30 days after the 
last tablet was taken. Participants were encour-
aged to record any side effects or adverse events 
in a diary that was reviewed at each trial visit, 
and they were specifically asked about such 
events during each telephone interview.
We assessed adherence by counting the tab-
lets that were returned by participants at each 
The New England Journal of Medicine 
Downloaded from nejm.org at GE HEALTHCARE LTD. on July 28, 2017. For personal use only. No other uses without permission. 
 Copyright © 2017 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 4
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
visit and by the participants’ reporting of tablet 
counts during each telephone interview. The 
total number of tablets taken was calculated by 
subtracting the number of tablets returned 
from the number of tablets prescribed. Adher-
ence was considered to be good if the reported 
intake of tablets was 85% or more of the total 
number that participants were expected to have 
taken between the date of randomization and 
the date of the visit at 36 weeks of gestation or 
the date of delivery if delivery occurred before 
36 weeks of gestation. Adherence was consid-
ered to be moderate if the intake was between 
50% and 84.9% and considered to be poor if it 
was less than 50%.
Statistical Analysis
The sample-size estimation was based on the 
assumption that first-trimester screening would 
detect 76% of the cases of preterm preeclampsia 
at a screen-positive rate of 10%.15 It was hypoth-
esized that low-dose aspirin would result in a rate 
of preterm preeclampsia that was 50% lower 
than the rate with placebo,8,9 for an estimated 
rate of 7.6% in the placebo group and 3.8% in 
the aspirin group. We calculated that the enroll-
ment of 1600 participants would give the trial 
90% power to show a treatment effect at a two-
sided alpha level of 5%. The target recruitment 
number was inflated to 1776 to account for 
attrition.
Statistical analyses were performed on an 
intention-to-treat basis, and no interim analyses 
were performed. Logistic-regression analysis was 
used to determine the significance of the between-
group difference in the incidence of preterm 
preeclampsia, with adjustment for the effect of 
the estimated risk of preeclampsia at screening 
and the participating center. The treatment ef-
fect was quantified as the odds ratio with a 95% 
confidence interval in the aspirin group. Pre-
specified analyses were also performed in sub-
groups that were categorized according to the 
estimated risk of preterm preeclampsia and his-
tory of preeclampsia; a post hoc subgroup analy-
sis was performed according to country of the 
participating centers. A sensitivity analysis was 
performed to take into account the effect of 
withdrawal of consent and loss to follow-up. We 
also produced Kaplan–Meier estimates of the 
cumulative incidence of preeclampsia according 
to trial group, in which deliveries that were not 
with preeclampsia were excluded. The treatment 
effect for the secondary outcomes was quanti-
fied as the odds ratio with a 99% confidence 
interval in the aspirin group, with adjustment 
for the effect of the estimated risk for pre-
eclampsia at screening and the participating 
center, and no corrections were made for mul-
tiple comparisons. The statistical software pack-
age R was used for data analyses.21
R esult s
Trial Participants
The trial started at King’s College Hospital, in the 
United Kingdom, in April 2014 but was stopped 
in June 2014 after the recruitment of 56 partici-
pants because of administrative problems with 
the supply of the trial products. The manufac-
ture and composition of the products were the 
same throughout the trial, and the women who 
were enrolled during this period were included 
in the trial population. The trial was restarted 
in July 2015, and recruitment was completed in 
April 2016.
A total of 26,941 women with singleton preg-
nancies underwent screening,15 and 2971 (11.0%) 
were found to be at high risk for preterm pre-
eclampsia. However, 332 of these women (11.2%) 
were excluded from recruitment to the trial be-
cause they did not fulfill the eligibility criteria 
(Fig. 1). Of the 2641 eligible women, 1776 (67.2%) 
agreed to participate in the trial. After random-
ization, 152 women (8.6%) withdrew consent. Of 
the women who participated in the trial, 4 were 
lost to follow-up.
There were no significant differences between 
the aspirin group and the placebo group with 
regard to the characteristics of the participants 
at baseline (Table 1). In the aspirin group, there 
were 11 miscarriages before 24 weeks of ges-
tation, 2 pregnancy terminations for fetal ab-
normalities at or before 24 weeks of gestation, 
1 pregnancy termination for severe fetal growth 
restriction and preeclampsia at 24 weeks of ges-
tation, 7 stillbirths at or after 24 weeks of gesta-
tion, 1 neonatal death within 28 days after birth, 
and 776 live births of infants who survived until 
discharge from the hospital. In the placebo 
group, there were 12 miscarriages before 24 weeks 
of gestation, 4 pregnancy terminations for fetal 
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abnormalities at or before 24 weeks of gestation, 
no pregnancy terminations for severe fetal growth 
restriction and preeclampsia at 24 weeks of ges-
tation, 12 stillbirths at or after 24 weeks of 
gestation, 2 neonatal deaths within 28 days after 
birth, and 792 live births of infants who survived 
to discharge from the hospital.
Primary Outcome
Preterm preeclampsia occurred in 13 of 798 par-
ticipants (1.6%) in the aspirin group, as compared 
with 35 of 822 (4.3%) in the placebo group (ad-
justed odds ratio in the aspirin group, 0.38; 95% 
confidence interval, 0.20 to 0.74; P = 0.004) (Ta-
ble 2). The size of the treatment effect was con-
sistent across estimated risk groups at the time 
of screening, across groups defined according to 
obstetrical history, and across countries of the 
participating centers (Figs. S1 and S2 in the Sup-
plementary Appendix). The cumulative percent-
ages of participants who had delivery with pre-
eclampsia are shown in Figure 2.
Of the 152 women who withdrew consent, 74 
did not want any of their data to be reported and 
78 allowed reporting of their screening data; the 
baseline characteristics of the women who with-
drew consent were similar between those as-
signed to receive aspirin and those assigned to 
Figure 1. Screening, Randomization, and Follow-up.
1776 Underwent randomization
2971 (11.0%) Were at high risk for preterm
preeclampsia
26,941 Women were screened for preterm
preeclampsia
332 Were excluded
253 Were receiving aspirin
47 Had hypersensitivity to aspirin
17 Had peptic ulcer or bleeding disorder
10 Participated in another drug trial
2 Had miscarriage before randomization
3 Had termination of pregnancy
before randomization
865 Declined to participate
878 Were assigned to receive aspirin 898 Were assigned to receive placebo
78 Withdrew consent
2 Were lost to follow-up
74 Withdrew consent
2  Were lost to follow-up
2641 Were eligible for inclusion
798 Were included in the primary analysis 822 Were included in the primary analysis
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Characteristic
Aspirin Group 
(N = 798)
Placebo Group 
(N = 822)
Gestational age at randomization — wk
Median 12.7 12.6
Interquartile range 12.3–13.1 12.3–13.0
Age — yr
Median 31.5 31.4
Interquartile range 27.3–35.8 26.9–35.8
Body-mass index†
Median 26.7 26.5
Interquartile range 23.3–31.1 23.0–31.5
Race or ethnic group — no. (%)‡
White 528 (66.2) 559 (68.0)
Black 208 (26.1) 201 (24.5)
South Asian 37 (4.6) 37 (4.5)
East Asian 13 (1.6) 16 (1.9)
Mixed race 12 (1.5) 9 (1.1)
Method of conception — no. (%)
Natural 747 (93.6) 779 (94.8)
Assisted by use of ovulation drugs 6 (0.8) 7 (0.9)
In vitro fertilization 45 (5.6) 36 (4.4)
Cigarette smoking — no. (%) 57 (7.1) 59 (7.2)
Mother had preeclampsia — no. (%) 66 (8.3) 74 (9.0)
Medical history — no. (%)
Chronic hypertension 49 (6.1) 61 (7.4)
Systemic lupus erythematosus 3 (0.4) 1 (0.1)
Antiphospholipid syndrome 2 (0.3) 2 (0.2)
Diabetes mellitus type 1 7 (0.9) 2 (0.2)
Diabetes mellitus type 2 8 (1.0) 8 (1.0)
Obstetrical history — no. (%)
Nulliparous 547 (68.5) 543 (66.1)
Multiparous without preeclampsia 164 (20.6) 195 (23.7)
Multiparous with preeclampsia 87 (10.9) 84 (10.2)
Interval from last pregnancy — yr
Median 4.2 4.6
Interquartile range 2.5–7.0 2.9–7.5
Gestational age at delivery of last pregnancy — wk 39 (37–40) 39 (36–40)
Risk of preterm preeclampsia as assessed at screening  
at 11–13 wk (95% CI) — %§
2.3 (1.4–4.8) 2.6 (1.5–4.8)
*  There were no significant between-group differences with regard to the characteristics at baseline. CI denotes confidence 
interval.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Race or ethnic group was reported by the participants.
§  The risk of preterm preeclampsia was assessed by means of an algorithm that combined maternal factors, mean arterial 
pressure, uterine-artery pulsatility index, and maternal serum pregnancy-associated plasma protein A and placental 
growth factor (see the Supplementary Appendix).
Table 1. Characteristics of the Trial Participants.*
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receive placebo (Table S2 in the Supplementary 
Appendix). A sensitivity analysis to evaluate the 
effect of the withdrawals22 showed no substan-
tive difference from the primary analysis (Fig. S3 
in the Supplementary Appendix).
Secondary Outcomes
The treatment effect for secondary outcomes, 
quantified as the odds ratio in the aspirin group 
with a 99% confidence interval, is shown in 
Tables 2 and 3, and in Figures S4 and S5 in the 
Supplementary Appendix. There was no signifi-
cant between-group difference in the incidence 
of any secondary outcomes, but the trial was not 
powered for these outcomes.
Adverse Events
In the aspirin group, at least one serious adverse 
event occurred in 13 participants (1.6%) and at 
least one adverse event occurred in 207 partici-
Outcome
Aspirin Group 
(N = 798)
Placebo Group 
(N = 822)
Odds Ratio 
(95% or 99% CI)*
Primary outcome: preterm preeclampsia at <37 wk of 
gestation — no. (%)
13 (1.6) 35 (4.3) 0.38 (0.20–0.74)
Secondary outcomes according to gestational age
Adverse outcomes at <34 wk of gestation
Any — no. (%) 32 (4.0) 53 (6.4) 0.62 (0.34–1.14)
Preeclampsia — no. (%) 3 (0.4) 15 (1.8) 0.18 (0.03–1.03)
Gestational hypertension — no. (%) 2 (0.3) 2 (0.2) 1.02 (0.08–13.49)
Small-for-gestational-age status without  
preeclampsia — no./total no. (%)†
7/785 (0.9) 14/807 (1.7) 0.53 (0.16–1.77)
Miscarriage or stillbirth without preeclampsia 
— no. (%)
14 (1.8) 19 (2.3) 0.78 (0.31–1.95)
Abruption without preeclampsia — no. (%) 1 (0.1) 3 (0.4) 0.36 (0.02–7.14)
Spontaneous delivery without preeclampsia  
— no. (%)
12 (1.5) 12 (1.5) 1.07 (0.37–3.10)
Adverse outcomes at <37 wk of gestation
Any — no. (%) 79 (9.9) 116 (14.1) 0.69 (0.46–1.03)
Gestational hypertension — no. (%) 8 (1.0) 7 (0.9) 1.19 (0.31–4.56)
Small-for-gestational-age status without  
preeclampsia — no./total no. (%)†
17/785 (2.2) 18/807 (2.2) 1.01 (0.42–2.46)
Miscarriage or stillbirth without preeclampsia 
— no. (%)
14 (1.8) 19 (2.3) 0.78 (0.31–1.95)
Abruption without preeclampsia — no. (%) 2 (0.3) 4 (0.5) 0.52 (0.06–4.91)
Spontaneous delivery without preeclampsia  
— no. (%)
40 (5.0) 49 (6.0) 0.83 (0.47–1.47)
Adverse outcomes at ≥37 wk of gestation
Any — no. (%) 178 (22.3) 171 (20.8) 1.12 (0.82–1.54)
Preeclampsia — no. (%) 53 (6.6) 59 (7.2) 0.95 (0.57–1.57)
Gestational hypertension — no. (%) 72 (9.0) 62 (7.5) 1.24 (0.78–1.98)
Small-for-gestational-age status without  
preeclampsia — no./total no. (%)†
54/785 (6.9) 56/807 (6.9) 1.00 (0.60–1.66)
Stillbirth without preeclampsia — no. (%) 2 (0.3) 2 (0.2) 1.01 (0.08–13.40)
Abruption without preeclampsia — no. (%) 2 (0.3) 2 (0.2) 1.05 (0.08–13.92)
*  The confidence interval was 95% for the primary outcome and 99% for the secondary outcomes.
†  The status of being small for gestational age was defined as a birth weight below the 5th percentile. The birth weight 
for neonates delivered before 24 weeks of gestation was not recorded.
Table 2. Outcomes According to Trial Group.
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pants (25.9%); in the placebo group, at least one 
serious adverse event occurred in 26 participants 
(3.2%) and at least one adverse event occurred in 
210 participants (25.5%). There was no significant 
between-group difference in the incidence of 
these events (Tables S3 and S4 in the Supple-
mentary Appendix).
 Adherence
Adherence was good in 1294 of 1620 partici-
pants (79.9%), moderate in 241 (14.9%), and poor 
in 85 (5.2%). There were no significant between-
group differences in the degree of adherence 
(Table S5 in the Supplementary Appendix). A 
sensitivity analysis that took into account adher-
ence to the assigned regimen is shown in Figure 
S6 in the Supplementary Appendix.
 Discussion
In this multicenter, randomized, placebo-con-
trolled trial involving women with singleton preg-
nancies who were identified by means of first-
trimester screening as being at high risk for 
preterm preeclampsia, the administration of 
aspirin at a dose of 150 mg per day from 11 to 
14 weeks of gestation until 36 weeks of gesta-
tion was associated with a significantly lower 
incidence of preterm preeclampsia than was 
placebo. There was no significant between-
group difference in the incidence of other preg-
nancy complications or of adverse fetal or 
neonatal outcomes. However, the trial was not 
adequately powered for the secondary outcomes.
Unlike previous trials of strategies to reduce 
the risk of preeclampsia among high-risk women, 
we identified women at high risk for preterm pre-
eclampsia by means of combined screening with 
maternal demographic characteristics and his-
torical factors and biomarkers — a strategy that 
has been shown to be superior to other cur-
rently used methods.11,13,14,23 Decisions regarding 
the gestational-age range at the onset of treat-
ment (11 to 14 weeks of gestation) and the pri-
mary outcome measure (preterm preeclampsia 
rather than total preeclampsia) were informed 
by the results of meta-analyses suggesting that 
aspirin confers greater benefit if it is started at 
or before 16 weeks of gestation and that preven-
tion is confined to preterm preeclampsia.8,9,24
The dose of 150 mg of aspirin per day was se-
lected on the basis of previous evidence of a 
dose-dependent benefit to therapy10; in addition, 
the commonly used dose of 81 mg of aspirin per 
day has no appreciable effect on platelet func-
tion in up to one third of pregnant women.25 The 
recommendation that participants take aspirin 
at night, rather than during the day, was based 
on the observation from a randomized trial that 
treatment at this time may be superior in reduc-
ing the rate of preeclampsia.26 The incidence of 
preterm preeclampsia in the placebo group was 
lower than what was anticipated (4.3%, vs. the 
expected value of 7.6%), and this finding is likely 
to be the consequence of differences between 
the demographic characteristics of the screened 
population and those of the population that was 
used for the development of the algorithm.
Screening at 11 to 13 weeks of gestation has 
been shown to identify less than 40% of cases of 
term preeclampsia.15 In our trial, aspirin did not 
reduce the incidence of term preeclampsia.
In conclusion, this randomized trial showed 
that among women with singleton pregnancies 
who were identified by means of first-trimester 
Figure 2. Kaplan–Meier Plot of Incidence of Delivery with Preeclampsia.
The gray box highlights the rate of preeclampsia before 37 weeks of gestation. 
Data were censored after deliveries not associated with preeclampsia. The 
inset shows the same data on an enlarged y axis.
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screening as being at high risk for preterm pre-
eclampsia, the administration of aspirin at a dose 
of 150 mg per day from 11 to 14 weeks of gesta-
tion until 36 weeks of gestation resulted in a 
significantly lower incidence of preterm pre-
eclampsia than that with placebo.
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Outcome
Aspirin Group 
(N = 798)
Placebo Group 
(N = 822) Odds Ratio (99% CI)
Stillbirth or death — no. (%)
All stillbirths or deaths 8 (1.0) 14 (1.7) 0.59 (0.19–1.85)
With preeclampsia or status of being small for  
gestational age
5 (0.6) 8 (1.0) 0.65 (0.15–2.90)
Without preeclampsia or status of being small for  
gestational age
3 (0.4) 6 (0.7) 0.51 (0.08–3.19)
With placental abruption or bleeding 0 2 (0.2) 0.00 (0.00–∞)
Without placental abruption or bleeding 8 (1.0) 12 (1.5) 0.69 (0.21–2.28)
Death or complications — no. (%)
Any 32 (4.0) 48 (5.8) 0.69 (0.37–1.27)
Miscarriage, stillbirth, or death 19 (2.4) 26 (3.2) 0.76 (0.35–1.68)
Intraventricular hemorrhage of grade ≥II 2 (0.3) 1 (0.1) 2.23 (0.09–52.70)
Sepsis with confirmed bacteremia in cultures 3 (0.4) 6 (0.7) 0.52 (0.08–3.32)
Anemia resulting in blood transfusion 5 (0.6) 11 (1.3) 0.47 (0.11–1.92)
Respiratory distress syndrome treated with surfactant  
and ventilation
11 (1.4) 22 (2.7) 0.53 (0.20–1.40)
Necrotizing enterocolitis resulting in surgery 2 (0.3) 1 (0.1) 2.10 (0.09–49.54)
Therapy — no. (%)
Any 55 (6.9) 60 (7.3) 0.97 (0.58–1.60)
Admission to intensive care unit 48 (6.0) 54 (6.6) 0.93 (0.55–1.59)
Ventilation with positive airway pressure or intubation 37 (4.6) 46 (5.6) 0.85 (0.47–1.52)
Poor fetal growth — no./total no. (%)*
Birth weight <3rd percentile 57/785 (7.3) 63/807 (7.8) 0.92 (0.57–1.51)
Birth weight <5th percentile 82/785 (10.4) 96/807 (11.9) 0.86 (0.57–1.30)
Birth weight <10th percentile 148/785 (18.9) 187/807 (23.2) 0.77 (0.56–1.06)
*  The birth weight for neonates who were delivered before 24 weeks was not recorded.
Table 3. Neonatal Outcomes According to Trial Group.
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